Addressing vaccine hesitancy in developing countries: Survey and experimental evidence

PLoS One. 2022 Nov 17;17(11):e0277493. doi: 10.1371/journal.pone.0277493. eCollection 2022.

Abstract

Vaccine hesitancy is proving to be a significant impediment to COVID-19 vaccination campaigns in some developing countries. This study focuses on vaccine hesitancy and means of reducing it. Data come from a large, representative phone survey and online randomized survey experiment, both run in Papua New Guinea, a developing country with low vaccination rates. Less than 20% of relevant respondents to the phone survey were willing to be vaccinated, primarily because of fear of side effects and low trust in the vaccine. Although vaccine hesitancy was high in the online experiment, participants who received a message emphasizing that the vaccine was safe and COVID-19 dangerous were 68% more likely to state they planned to be vaccinated than those in the control group. A message appealing to social norms was also effective in reducing vaccine hesitancy, although its efficacy was limited to certain types of people.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Developing Countries
  • Humans
  • Patient Acceptance of Health Care
  • Surveys and Questionnaires
  • Vaccination Hesitancy
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines

Grants and funding

Funding for this study was provided by Gavi, the Vaccine Alliance; the Korea Trust Fund for Economic and Peace-Building Transitions; and The United States Agency for International Development (through the Papua New Guinea UNICEF office). The funders played no role in the the study design, data collection and analysis, decision to publish, or preparation of the manuscript.